Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplant Recipients: A Global Perspective

. Author manuscript; available in PMC: 2011 May 27.

Published in final edited form as: Biol Blood Marrow Transplant. 2009 Oct;15(10):1143–1238. doi: 10.1016/j.bbmt.2009.06.019

Pathogen: Bordetella pertussis

Indication	First Choice	Alternatives
Immunization against pertussis for adult or pediatric HCT recipients	Acellular pertussis vaccine Initial dose at 6–12 months post-HCT A total of 3 doses should be given at least 1 month apart	Azithromycin orally daily for persons with incomplete vaccination series *Adults and adolescents:* 250 mg *Pediatrics:* 5 mg/kg daily
Postexposure prophylaxis for adult or pediatric HCT recipients, regardless of vaccination status	Azithromycin: *Adults and adolescents:* 500 mg for 1 day then 250 mg daily for 4 days *Pediatrics:* 10 mg/kg loading dose then 5 mg/kg daily for 4 days